Prana Biotechnology is developing first-in-class therapies to treat neurodegenerative disease.
The Company's lead drug candidate – PBT2 – is being developed for the treatment of Alzheimer’s and Huntington's diseases. The Company is targeting lodgement of a New Drug Application for Huntington's disease in 2016/2017 pending positive trial results.
Prana Biotechnology also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Development of PBT434 has received funding from the Michael J. Fox Foundation and Parkinsons UK.
The Company has a library of more than 1000 Metal Protein Attenuating Compounds (MPACs) which may support new therapies for neurodegenerative disease and other highly prevalent conditions. Other potential applications for this platform technology include specific cancers.
The earliest beginnings of Prana Biotechnology began in the laboratory of Professor Rudolph Tanzi at Massachusetts General Hospital in the 1980s when he was investigating the molecular and genetic basis of neurological disease.
Prana Biotechnology was incorporated in Melbourne, Australia in 1997. The Company listed on the Australian Securities Exchange (ASX: PBT) in 2000 and listed on the NASDAQ (NASDAQ: PRAN) in 2002.
Board of Directors
Prana has a well established Board of Directors with extensive experience in the research, pharmaceutical and financial industries.
Research and Development Advisory Board
The Research and Development Advisory Board is composed of scientists with professional expertise in research. These scientific advisors provide advice regarding the Company‘s proposed research and development activities
Chief Scientific Advisor, Scientific Co-Founder, Professor of Neurology, Harvard Medical School
Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention at the University of Edinburgh
Mental Health Research Institute; Laureate Professor at the University of Melbourne